Loading filters...
Publications per Year (1849 total)
14
1990
18
·
17
·
20
·
16
·
22
1995
10
·
30
·
35
·
33
·
38
2000
40
·
39
·
34
·
46
·
61
2005
52
·
66
·
55
·
66
·
69
2010
70
·
91
·
62
·
75
·
81
2015
69
·
63
·
63
·
65
·
65
2020
78
·
66
·
73
·
52
·
59
2025
36
·
Loaded
Click to load
50 / 1849 papers loaded(scroll for more)
202636 papers
OsteosarcomaAll Stages2026
Spermidine Secreted by Apoptotic Cells Enhances Chemotherapy Resistance by Modulating β-Catenin Activity in Osteosarcoma.
Yu Q et al. Clin Cancer Res. 2026
LiposarcomaAll Stages2026
Well-Differentiated Liposarcoma of the Psoas Muscle: A Distinct Anatomic Subset with Highly Favorable Outcomes.
Tseng WW et al. Ann Surg Oncol. 2026
Soft Tissue SarcomaAdvanced/Metastatic2026
Trabectedin-olaparib combination or trabectedin in advanced soft tissue sarcomas after failure of anthracycline-based treatment (TOMAS2): a randomized phase II study from the Italian Sarcoma Group.
D'Ambrosio L et al. Ann Oncol. 2026
Ewing SarcomaAll Stages2026
Multicenter Histology Image Integration and Multiscale Deep Learning Support Machine Learning-Enabled Pediatric Sarcoma Classification.
Thiesen AH et al. Cancer Res. 2026
GISTearly2026
Optimizing Surgical Strategies and Prognostic Outcomes in Duodenal Gastrointestinal Stromal Tumors.
Sun X et al. Ann Surg Oncol. 2026
Ewing SarcomaAll Stages2026
Validation of a Seven-Gene Predictive SIGNature for the Efficacy of Immuno-Oncology PD-1 Inhibitors in Patients with Sarcoma.
Moura DS et al. Clin Cancer Res. 2026
Soft Tissue SarcomaAdvanced/Metastatic2026
A randomized clinical study comparing trabectedin combined with regional hyperthermia with trabectedin in patients with advanced soft tissue sarcoma: HyperTET, a German Interdisciplinary Sarcoma Group trial.
Schuebbe GE et al. ESMO Open. 2026
LiposarcomaAdvanced/Metastatic2026
Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial.
Schöffski P et al. Clin Cancer Res. 2026
Soft Tissue SarcomaAll Stages2026
Pleomorphic rhabdomyosarcoma, outcomes of patients with advanced disease treated with systemic agents: Retrospective study from the global pushing ultra-rare sarcomas towards hope (PUSH) consortium.
Baldi GG et al. Eur J Cancer. 2026
Ewing SarcomaAdvanced/Metastatic2026
PRECLINICAL ACTIVITY OF THE B7-H3- TARGETING ANTIBODY-DRUG CONJUGATE (ADC) VOBRAMITAMAB DUOCARMAZINE (VOBRA DUO) IN PEDIATRIC SOLID TUMORS.
Favours E et al. Clin Cancer Res. 2026
GISTAdvanced/Metastatic2026
Cancer-Associated Fibroblasts Promote Imatinib Resistance in Gastrointestinal Stromal Tumors through PGK1-Mediated Metabolic Reprogramming.
Li C et al. Cancer Res. 2026
Ewing SarcomaAdvanced/Metastatic2026
An open-label, two-cohort, phase 1a/b study of weekly irinotecan hydrochloride liposome injection combined with vincristine and temozolomide (NALIRI-VT) in patients with advanced Ewing sarcoma.
Zhao Y et al. Eur J Cancer. 2026
LiposarcomaAll Stages2026
Targeting the Non-Homologous End Joining Pathway Sensitizes MDM2-Amplified Liposarcoma to Doxorubicin by Enhancing p53-Mediated Senescence.
Jalving T et al. Cancer Res. 2026
Liposarcomaearly2026
Safety of Pre-Operative Radiotherapy Combined With Intraoperative Radiotherapy for Retroperitoneal Sarcoma.
MacDonald M et al. J Surg Oncol. 2026
Liposarcomaearly2026
Surgical Management of Recurrent Retroperitoneal Sarcomas: Experience From a High-Volume Sarcoma Centre: Recurrent Retroperitoneal Sarcomas: Outcomes of Multiple Recurrences.
Kaderi ASA et al. J Surg Oncol. 2026
LiposarcomaAll Stages2026
Pancreaticoduodenectomy and IVC resection in retroperitoneal sarcoma: Expanding the limits of feasible surgery.
Benuzzi L et al. Eur J Surg Oncol. 2026
Ewing SarcomaAdvanced/Metastatic2026
IL1RAP antibody-drug conjugates potently target primary and metastatic disease in multiple oncofusion-driven cancers.
Zhang HF et al. Cancer Discov. 2026
LiposarcomaAll Stages2026
Overall survival from the open-label phase II trial of palbociclib in patients with advanced well-differentiated/dedifferentiated liposarcoma.
Babatunde OO et al. ESMO Open. 2026
Ewing SarcomaAdvanced/Metastatic2026
Interest of a sequential multimodal approach for the treatment of newly diagnosed patients with multimetastatic Ewing sarcoma: results of the French prospective CombinaiR3 phase II trial.
Laurence V et al. Br J Cancer. 2026
Soft Tissue SarcomaAdvanced/Metastatic2026
Clinical, immunological, and genomic findings of atezolizumab in advanced alveolar soft part sarcoma: A phase II trial (ALBERT trial/NCCH1907).
Kojima Y et al. Eur J Cancer. 2026
Ewing SarcomaAdvanced/Metastatic2026
Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial.
Gatz SA et al. Clin Cancer Res. 2026
Soft Tissue SarcomaAdvanced/Metastatic2026
First-line Anlotinib plus Anthracyclines and Ifosfamide Followed by Anlotinib Maintenance in Advanced Soft-Tissue Sarcoma: A Phase II Single-Arm Trial.
Zhao JK et al. Clin Cancer Res. 2026
Soft Tissue SarcomaAdvanced/Metastatic2026
Phase IB/II Trial with Correlative Analyses of Doxorubicin plus Durvalumab Combination in Patients with Advanced Soft Tissue Sarcoma.
Yun KH et al. Clin Cancer Res. 2026
LiposarcomaAll Stages2026
Clinical Course and Dedifferentiation of Atypical Lipomatous Tumors: A Retrospective Analysis of Surveillance and Surgical Management.
Hakkesteegt SN et al. Ann Surg Oncol. 2026
Ewing SarcomaAll Stages2026
FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy.
Gracilla DE et al. Cancer Res. 2026
Soft Tissue SarcomaAdvanced/Metastatic2026
Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trial.
Grohar PJ et al. Nat Med. 2026
Ewing SarcomaAll Stages2026
Addition of zoledronic acid to consolidation chemotherapy in Ewing sarcoma-EURO EWING 2012 (EE2012): an international, open-label, randomised controlled phase III trial.
Bernadette B et al. Br J Cancer. 2026
LiposarcomaAdvanced/Metastatic2026
Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: The Phase 2 DOREMY Nonrandomized Clinical Trial.
Lansu J et al. JAMA Oncol. 2026
LiposarcomaAll Stages2026
Vascular Reconstruction in Extremity Soft Tissue Sarcomas: A Systematic Review and Single-Arm Meta-Analysis.
Delgado LM et al. J Surg Oncol. 2026
Ewing SarcomaAll Stages2026
Comparison of Presentation and Management in Skeletal and Extraskeletal Ewing Sarcoma in Children.
Chidiac C et al. J Surg Oncol. 2026
LiposarcomaAll Stages2026
First-in-Human Study of CEB-01: Novel Loco-Regional SN-38-Releasing Membrane to Prevent Local Recurrence in Retroperitoneal Sarcomas.
Gonzalez JA et al. Ann Surg Oncol. 2026
LiposarcomaAll Stages2026
Bayesian sequential learning for prognostication in extremity soft tissue sarcoma (BayeSarc): a retrospective, multicentre cohort study.
Callegaro D et al. Lancet Oncol. 2026
GISTearly2026
Laparoscopic versus open surgery for locally advanced gastric gastrointestinal stromal tumors following neoadjuvant imatinib therapy: a multicenter propensity-weighted cohort study.
Cai Z et al. Eur J Surg Oncol. 2026
GISTearly2026
Deep Learning Predicts Mutations and Outcomes in Gastrointestinal Stromal Tumors from Whole-Slide Images.
Bonetti A et al. Cancer Res. 2026
Soft Tissue SarcomaAll Stages2026
Activity of chemotherapy in mesenchymal chondrosarcoma: a multicentre retrospective analysis within the Italian Sarcoma Group network.
Baldi GG et al. ESMO Open. 2026
Ewing SarcomaAll Stages2026
A first-in-pediatric study of ALRN-6924, a novel stapled-peptide dual MDM2/MDMX inhibitor, for children with advanced hematologic and solid malignancies.
Shulman DS et al. Clin Cancer Res. 2026
202514 papers
Ewing Sarcomaearly2025
Mapping Knowledge Structure and Themes Trends of Ewing Sarcoma: A Text-Mining Study.
Wu H et al. Ann Surg Oncol. 2025
LiposarcomaAll Stages2025
The Impact of Perioperative Radiotherapy on Disease-Specific Survival in Patients with Localized Retroperitoneal Liposarcoma: A Population-Based Propensity-Score Matched Analysis.
Wilhelm A et al. Ann Surg Oncol. 2025
LiposarcomaAdvanced/Metastatic2025
The role of whole-genome sequencing for guiding systemic therapy in patients with soft tissue sarcoma.
van der Laan P et al. ESMO Open. 2025
Liposarcomaearly2025
Sarcoma: Last Year's Practice Changing Papers.
van Houdt WJ et al. Ann Surg Oncol. 2025
LiposarcomaAdvanced/Metastatic2025
Pleomorphic Liposarcoma of the Extremity and Trunk: Multimodality Therapy for Some but Not All?
Tseng WW et al. J Surg Oncol. 2025
Liposarcomaearly2025
Radiologic and Pathologic Response Evaluation After Neoadjuvant Chemotherapy for Primary Retroperitoneal Sarcoma: A Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG) Collaboration.
van der Burg SJC et al. Ann Surg Oncol. 2025
GISTAll Stages2025
Intratumoral Bacteria are Uncommon in Gastrointestinal Stromal Tumor.
Tardy KJ et al. Ann Surg Oncol. 2025
LiposarcomaAdvanced/Metastatic2025
Immunocompetent Murine Models Recapitulate the Heterogeneous Tumor-Immune Microenvironment of Human Liposarcoma.
Shafer AM et al. Clin Cancer Res. 2025
Ewing SarcomaAll Stages2025
SARC028 Samples Reveal an Interplay between TGF-β, IFN Signaling, and Low HLA Class I Expression as Contributors to Ewing Sarcoma Checkpoint Blockade Resistance.
Daley JD et al. Clin Cancer Res. 2025
Ewing SarcomaAdvanced/Metastatic2025
Single-Cell RNA Sequencing of Ewing Sarcoma Tumors Demonstrates Transcriptional Heterogeneity and Clonal Evolution.
Goodspeed A et al. Clin Cancer Res. 2025
Ewing Sarcomaearly2025
Evaluating the Role of Surgical Resection and Reconstruction in the Management of Ewing sarcoma of the Chest Wall in the Paediatric Population: A Systematic Review.
Rice D et al. J Surg Oncol. 2025
Soft Tissue SarcomaAdvanced/Metastatic2025
Ossifying fibromyxoid tumours: A case series.
Pozas J et al. Eur J Cancer. 2025
GISTearly2025
Adjuvant treatment of gastrointestinal stromal tumor: State of the art in 2025.
Penel N et al. Eur J Cancer. 2025
Soft Tissue SarcomaAdvanced/Metastatic2025
Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial.
Penel N et al. Ann Oncol. 2025